<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00571779</url>
  </required_header>
  <id_info>
    <org_study_id>CP2007-2</org_study_id>
    <nct_id>NCT00571779</nct_id>
  </id_info>
  <brief_title>AtriCure Minimally Invasive Surgical Ablation for Atrial Fibrillation/RESTORE IIB</brief_title>
  <acronym>RESTORE SR IIB</acronym>
  <official_title>Thoracoscopically-Assisted Epicardial Bilateral Pulmonary Vein Isolations Using the AtriCure Bipolar System and Exclusion of the Left Atrial Appendage for the Treatment of Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AtriCure, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AtriCure, Inc.</source>
  <brief_summary>
    <textblock>
      Feasibility study arm to evaluate the safety of adding the left atrial linear connecting&#xD;
      lesions of the Cox-Maze lesion set to the current RESTORE SR II IDE study procedure of&#xD;
      performing pulmonary vein isolation, selected left atrial autonomic ganglionated plexi (GP)&#xD;
      ablation, and optional left atrial appendage (LAA) excision/exclusion on a beating heart for&#xD;
      patients with permanent or persistent Atrial Fibrillation (AF).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Feasibility of performing the operation by demonstrating the ability to consistently isolate the left and right pulmonary veins and to confirm conduction block across the roof, anterior and LAA linear lesions.</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>The primary safety endpoint will be determined by assessing the rate of serious adverse events.</measure>
  </primary_outcome>
  <condition>Atrial Fibrillation</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AtriCure Bipolar System</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient between 18 and 80 years of age&#xD;
&#xD;
          2. Patient with documented symptomatic persistent or permanent AF and failure or&#xD;
             intolerance of one or more Class I or Class III antiarrhythmic drugs.&#xD;
&#xD;
               -  Persistent AF: AF that is not self-terminating or is terminated electrically or&#xD;
                  pharmacologically.&#xD;
&#xD;
               -  Longstanding AF: Persistent AF of 12 months (or longer) duration.&#xD;
&#xD;
               -  Permanent AF: Longstanding AF in which electrical or pharmacological&#xD;
                  cardioversion has failed or has not been attempted.&#xD;
&#xD;
          3. Patient is willing and able to provide written informed consent.&#xD;
&#xD;
          4. Patient has a life expectancy of at least 2 years.&#xD;
&#xD;
          5. Patient is willing and able to attend the scheduled follow-up visits.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior cardiac catheter ablation for the treatment of arrhythmia within 4 months.&#xD;
&#xD;
          2. Patients who refuse, but have not failed and can tolerate anti-arrhythmic medications&#xD;
&#xD;
          3. Myocardial infarction within 8 weeks.&#xD;
&#xD;
          4. Prior cardiac surgery.&#xD;
&#xD;
          5. Patient requires cardiac surgery for treatment other than for AF.&#xD;
&#xD;
          6. Class IV NYHA heart failure symptoms, unless due to uncontrolled AF&#xD;
&#xD;
          7. Cerebrovascular accident within previous 6 months&#xD;
&#xD;
          8. Known carotid artery stenosis greater than 80%&#xD;
&#xD;
          9. Evidence of significant active infection&#xD;
&#xD;
         10. Patient unable to undergo TEE&#xD;
&#xD;
         11. Pregnant woman&#xD;
&#xD;
         12. Patient requires anti-arrhythmic drug therapy for the treatment of ventricular&#xD;
             arrhythmia&#xD;
&#xD;
         13. Presence of thrombus in the left atrium&#xD;
&#xD;
         14. Co-morbid condition that in the opinion of the investigator poses undue risk of&#xD;
             general anesthesia or port access cardiac surgery&#xD;
&#xD;
         15. Patient is enrolled in another cardiac clinical trial&#xD;
&#xD;
         16. Left ventricular ejection fraction &lt; 30%&#xD;
&#xD;
         17. Left atrial transverse diameter &gt;6.0&#xD;
&#xD;
         18. Patient has undergone previous thoracic targeted radiation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>February 2011</verification_date>
  <study_first_submitted>December 10, 2007</study_first_submitted>
  <study_first_submitted_qc>December 10, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2007</study_first_posted>
  <last_update_submitted>February 18, 2011</last_update_submitted>
  <last_update_submitted_qc>February 18, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2011</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

